| Abstrakt: |
A recent study conducted by researchers at Rostock University Medical Center in Germany has provided new data on personalized medicine for head and neck squamous cell carcinoma (HNSCC). The study found that patients with high expression of the CMTM6 biomarker had longer overall survival rates, regardless of treatment. Additionally, the combination of CMTM6, FOXP3, PD-L1, and CTLA-4 markers showed promise as a prognostic and predictive signature for HNSCC patients, potentially optimizing individualized treatments. The study also revealed that PD-L1 positivity was associated with longer progression-free survival in chemotherapy-treated patients. [Extracted from the article] |
